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This randomised phase III study in advanced non-small cell lung cancer (NSCLC) patients was conducted to compare vinorelbine/
carboplatin (VC) and gemcitabine/carboplatin (GC) regarding efficacy, health-related quality of life (HRQOL) and toxicity.
Chemonaive patients with NSCLC stage IIIB/IV and WHO performance status 0–2 were eligible. No upper age limit was defined.
Patients received vinorelbine 25mgm
 2 or gemcitabine 1000mgm
 2 on days 1 and 8 and carboplatin AUC4 on day 1 and three
courses with 3-week cycles. HRQOL questionnaires were completed at baseline, before chemotherapy and every 8 weeks until 49
weeks. During 14 months, 432 patients were included (VC, n¼218; GC, n¼214). Median survival was 7.3 vs 6.4 months, 1-year
survival 28 vs 30% and 2-year survival 7 vs 7% in the VC and GC arm, respectively (P¼0.89). HRQOL, represented by global QOL,
nausea/vomiting, dyspnoea and pain, showed no significant differences. More grade 3–4 anaemia (Po0.01), thrombocytopenia
(Po0.01) and transfusions of blood (Po0.01) or platelets (Po0.01) were observed in the GC arm. There was more grade 3–4
leucopoenia (Po0.01) in the VC arm, but the rate of neutropenic infections was the same (P¼0.87). In conclusion, overall survival
and HRQOL are similar, while grade 3–4 toxicity requiring interventions are less frequent when VC is compared to GC in advanced
NSCLC.
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Lung cancer remains the leading cause of cancer death worldwide,
and the incidence is increasing (Jemal et al, 2006). Non-small cell
lung cancer (NSCLC) accounts for about 80% of lung cancer cases,
and the majority presents with locally advanced or metastatic
disease (Ries et al, 2006). The patient population is large, median
age high and comorbidity often considerable. Optimising the
treatment is a challenge. Any systemic anticancer therapy to this
group should be effective, tolerable and improve quality of life
(QOL).
In the meta-analysis from 1995 (Alberti, 1995) demonstrated
superiority of chemotherapy over best supportive care in advanced
NSCLC. Since then, new agents like vinorelbine, gemcitabine,
taxans and irinotecan, often referred to as third-generation drugs,
have established their role in this disease. The third-generation
agents have been compared to older regimens in various ways.
Platinum-based doublets with a third-generation drug have proven
more effective than monotherapy, and equally effective, but less
toxic, than three-drug regimens (Bunn, 2002). Two-drug combina-
tion regimens have been established as recommended first-line
chemotherapy in advanced NSCLC (Pfister et al, 2004). Although
slightly inferior to cisplatin (Hotta et al, 2004), carboplatin is
advocated a valuable alternative in the palliative treatment of
NSCLC. Which third-generation non-platinum agent to choose is,
however, still debated.
Vinorelbine/carboplatin (VC) and gemcitabine/carboplatin (GC)
are both third-generation combinations used in the treatment of
NSCLC. Vinorelbine in combination with a platinum-compound is
established as treatment of advanced NSCLC (Kelly et al, 2001;
Scagliotti et al, 2002; Plessen et al, 2006). The gemcitabine/
platinum combination is widely used and reported to be effective
and tolerable (Le Chevalier et al, 2005). The aim of the present
study was to compare VC and GC with respect to efficacy, health-
related quality of life (HRQOL) and toxicity in stage IIIB/IV
NSCLC patients. The inclusion criteria were liberal, reflecting the
everyday clinical situation. To our knowledge, this is the first
randomised direct comparison of these two regimens.
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Patients
In this national, multicentre and randomised phase III trial,
chemonaive patients with histologically or cytologically confirmed
NSCLC stage IIIB or IV, not candidates for curative treatment, were
included. Eligibility criteria were WHO performance status (PS) 0–2
and ability to understand oral and written study information. No
upper age limit was defined. White blood-cell count 43.0 10
9cells
l
 1,p l a t e l e tc o u n t4100 10
9cells l
 1,s e r u mc r e a t i n i n o1.5 times
upper reference limit and bilirubin and serum transaminase
levelso2 times upper limits were required. Exclusion criteria were
other active malignancies, pregnancy, or breast feeding.
The Regional Ethical Review Board, the Norwegian Social
Science Data Services and the Norwegian Medicines Agency have
approved the study.
Baseline investigation
At study entry, all patients underwent clinical examinations,
laboratory measures, chest X-ray and chest CT scan including
upper abdomen. PS, body weight and height were registered.
Patients were staged according to the clinical stage classification
from 1997 (Mountain, 1997).
Randomisation
After signing the informed consent and completing the baseline
HRQOL form, patients were randomised to receive VC or GC,
stratifying for PS 0–1 vs 2 and stage IIIB vs IV. Randomisation was
performed by phone or fax to the randomisation centre (Clinical
Cancer Research Office, University Hospital of Northern Norway).
Chemotherapy
In each arm, three courses of chemotherapy, primarily adminis-
tered on an outpatient basis, were given at 3-week cycles.
Carboplatin was administered on day 1, and vinorelbine or
gemcitabine on days 1 and 8 in each course. For both regimens, the
carboplatin dose was calculated by the Chatelut formula (Chatelut
et al, 1995) using AUC¼4, which approximates Calvert (Calvert
et al, 1989) AUC¼5.
Carboplatin in 500ml 5% glucose was administered as a 1-h
infusion. Vinorelbine 25mgm
 2 in 100ml 5% glucose was given as
a 10min i.v. infusion, whereas gemcitabine 1000mgm
 2 in 250ml
0.9% NaCl was administered i.v. for 30min. Patients X75 years
received 75% of standard doses. Antiemetics were given before
chemotherapy.
Blood counts were assessed weekly. If moderate haematological
toxicity (WBC: 2.5 2.99 10
9l
 1 and/or platelets: 75–99 10
9l
 1
occurred at days 1 and 8, doses were reduced by 25%. In case of
severe haematological toxicity (WBCo2.5 10
9l
 1 and/or plate-
letso 75 10
9l
 1), chemotherapy was postponed for 1 week and
further doses were reduced by 25%. If treatment was associated
with febrile leucopoenia or leucopoenia-associated infection,
chemotherapy was postponed until clinical recovery and further
doses were reduced by 25%. Treatment was discontinued in case of
disease progression, unacceptable toxicity or on patient’s request.
Patient follow-up
At start of each treatment cycle (weeks 0, 3 and 6) and at the
8-weekly follow-up visits (weeks 9, 17, 25, 33, 41 and 49), patients
underwent clinical examinations, evaluations of PS, assessments of
body weight, laboratory tests and chest X-rays. For evaluation of
disease progression, chest CT was performed when indicated.
Haematological toxicity was graded according to the WHO
toxicity criteria (WHO, 1979). Transfusions, bleedings, leuco-
poenic infections, use of G-CSF or erythropoietin and hospital
admissions due to treatment toxicity were registered. The use of
radiotherapy or second-line chemotherapy was recorded.
Site visits were performed at hospitals, which included X20
patients. Otherwise, missing data were retrieved through phone or
mail to the patient’s physician.
Assessment of HRQOL
HRQOL was assessed using the European Organization for
Research and Treatment of Cancer (EORTC) Quality of Life
Questionnaire (QLQ)-C30 (Aaronson et al, 1993) and the lung
cancer-specific module QLQ-LC13. (Bergman et al, 1994) The
QLQ-C30 measures fundamental aspects of HRQOL and symptoms
commonly reported by cancer patients in general, while the QLQ-
LC13 addresses symptoms specifically associated with lung cancer
and its treatment.
Baseline HRQOL questionnaires were completed before the first
chemotherapy cycle. Follow-up questionnaires (before each cycle
and every 8 weeks until 49 weeks) were mailed to the patients from
the randomisation office. In lack of response, one reminder was
mailed after 14 days.
Study endpoints
The main endpoint was overall survival. Further endpoints were
patient-assessed HRQOL and treatment toxicity including required
interventions. Global QOL, nausea/vomiting, dyspnoea and pain
during the first 17 weeks were pre-defined as the primary HRQOL
items of interest.
Global QOL is an important general measure, nausea/vomiting a
common side effect of chemotherapy and dyspnoea a severe
symptom in lung cancer. Pain is frequent in stage IV disease with a
significant impact on QOL.
Statistical considerations
Estimation of study size was based both on survival and HRQOL
measures. To detect a difference in survival of 11% or HRQOL of
15% between the groups, provided a power of 80% and a
significance level of 0.05 using two-sided tests, 380 patients were
required. Based on a 5% dropout, the required patient number was
400.
Survival, defined as time from randomisation to the date of
death, was compared using Kaplan–Meier estimates and the log-
rank test.
HRQOL items for global QOL, nausea/vomiting, dyspnoea and
pain were scored for each patient according to the EORTC QLQ-
C30 scoring manual (Fayers et al, 2001). All HRQOL item scores
range from 0 to 100. A high score in global QOL represents a good
QOL, whereas a high symptom-scale score represents more
symptoms. For group comparisons of baseline scores during and
after chemotherapy, and changes in scores from baseline, the
Mann–Whitney U-test was used. A mean change of X10 was
considered clinically relevant and significant (Osoba et al, 1998).
The AUC from baseline to week 17 was compared using a two-
sided t-test. Group differences consistent across all three methods
of analysis, or yielding a P-value p0.01, were considered
significant.
Differences in haematological toxicity and registered interven-
tions were analysed using two-sided t-test and w
2 tests.
RESULTS
Patients
Between October 2003 and December 2004, 444 patients from 33
hospitals in Norway were randomised to receive VC (n¼222) or
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months). Ten patients were randomised prematurely and later
failed to meet the inclusion criteria (SCLC, n¼2; stage IIB–IIIA
disease, n¼5; malignant melanoma, n¼1; carcinoid, n¼1;
granulomatous disease, n¼1). Furthermore, two patients were
randomised without giving their consent. In total, 432 patients, 218
in the VC and 214 in the GC arm, met the eligibility criteria and
constituted the intention-to-treat population for the primary end-
point analysis. This accounts for grossly 40% of all stage IIIB–IV
NSCLC patients diagnosed in Norway during the study period
(personal communication, The Norwegian Cancer Registry).
Nine hospitals recruited X20 patients, constituting 70% of the
total patient population. The patient flow chart is presented in
Figure 1.
Patient characteristics according to treatment groups are given
in Table 1. For all patients, median age was 67 years, 20% X75-
years old, 61% male, 71% had stage IV disease, 28% PS 2 and 48%
adenocarcinoma. The study arms were well balanced with respect
to demographic, clinical and histological characteristics.
Chemotherapy completion
The mean number of chemotherapy courses was 2.7 for the VC and
2.6 for the GC arm. Reasons for treatment termination are given in
Figure 1. In the VC arm, 180 patients (83%) received all three
cycles, 21 (10%) two cycles, 15 (7%) one cycle and two (1%) no
chemotherapy. In the GC arm, the corresponding numbers were
167 (78%), 17 (8%), 26 (12%) and 4 (2%).
Delayed or cancelled vinorelbine or gemcitabine at day 8 due to
haematological toxicity was observed in 9.3% (delayed 4.6%; not
given 4.8%) of the VC and 18.1% (delayed 10.2%; not given 7.9%)
of the GC group (P¼0.03). Time exceeding 24 days between the
main chemotherapy courses occurred in 15% of VC and 23% of GC
patients (P¼0.06).
Survival
All enrolled patients were included in the survival analyses
(n¼432). There was no difference in overall survival between
the treatment arms (P¼0.89; Figure 2A). The median survival was
7.3 vs 6.4 months and the 1- and 2-year survival were 28 and 7% vs
30 and 7%, respectively, for the VC and GC arm. Excluding the PS
2 patients, the corresponding median survival was 9.0 vs 8.9
months, while the 1- and 2-year survival were 35 and 9% vs 38 and
8%, respectively (P¼0.75; Figure 2B).
The cause of death was recorded in 324 patients. As reported by
the local investigators, 282 deaths (87%) were caused by lung
cancer. Six deaths were associated with chemotherapy side effects
(VC, n¼2; GC, n¼4), while the remaining (n¼36) were classified
as other causes.
QOL
The compliance rate with respect to completion of the HRQOL
questionnaires was 95 and 98% at baseline and declined to
minimum 61 and 60% during the 49-week follow-up for the VC
and GC arm, respectively. Mean score analyses were performed for
all patients, while only patients with completed baseline HRQOL
questionnaires were included in the mean change analyses (VC,
n¼207; GC, n¼210). The AUC was analysed for patients who had
completed all five questionnaires during the period of interest (VC,
n¼111; GC, n¼97). Mean scores for global QOL, nausea/
vomiting, dyspnoea and pain are shown in Figure 3. Mean scores
at baseline and weeks 3, 6, 9 and 17 were compared between the
treatment arms. The GC arm tended to have slightly worse scores
than the VC arm for nausea/vomiting and dyspnoea during
therapy, but there were no significant differences for any of the
four examined HRQOL items. Neither was there any difference
between the VC and GC arm with respect to mean change of scores
or AUC from baseline to week 17 (data not shown).
Toxicity and required interventions
Data on haematological toxicity are presented in Table 2. More
grade 3–4 anaemia and thrombocytopenia were observed in the
Randomised (n=444)
Excluded (n=12, VC=4, GC=8)
  Not meeting inclusion criteria
(n=10)
  Refused to participate
(n=2)
Survival analysis (n=218).
Toxicity analysis (n=216), 2 pts
without treatment excluded.
QOL mean score analyses (n=218).
QOL mean change analyses (n=208),
10 patients without baseline QLQ
excluded.   
Discontinued treatment (n=36):
Disease progression n=18 
Treatment toxicity   n=6 
Patients wish           n=1 
Intercurrent disease n=7 
Other reasons          n=4 
Allocated to VC (n=218)
Received intervention (n=216) 
Did not receive intervention (n=2):
acute deterioration of performance
status
Discontinued treatment (n= 43):
Disease progression n=15 
Treatment toxicity     n=6 
Patients wish            n=5 
Intercurrent disease  n=6 
Other reasons           n=11
Allocated to GC (n=214)
Received intervention (n=210)
Did not receive intervention (n=4):
acute serious illness (n=3) and
acute deterioration of performance
status (n=1) 
Survival analysis (n=214).
Toxicity analysis (n=210), 4 pts
without treatment excluded.
QOL mean score analyses (n=214).
QOL mean change analyses (n=210),
5 patients without baseline QOL
excluded.  
Allocation
Analysis 
Follow-up
Enrolment
(n=432)
Figure 1 Flow of patients through each stage of the study.
Table 1 Patient characteristics at inclusion according to treatment arm
VIN/CARBO GEM/CARBO
(n¼218) (n¼214)
Characteristics n % n % P
Age (years)
Median 67 67 0.92
Range 37–86 37–85
Sex
Female 90 41 78 36 0.30
Male 128 59 136 64
Performance status
0/1 156 72 153 71 0.99
26 2 2 8 6 1 2 9
Extent of disease
Stage IIIB 65 30 60 28 0.68
Stage IV 153 70 154 72
Histology
Squamous cell carcinoma 58 26 52 24 0.65
Adenocarcinoma 108 50 101 47
Large cell carcinoma 11 5 19 9
Other 41 19 42 20
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the VC arm (Po0.01). Other treatment side effects and required
interventions are given in Table 3. More patients in the GC arm
needed blood transfusions (Po0.01) or platelets (P¼0.04), while
there was no difference between the arms with respect to
neutropenic infections (P¼0.98). Patients in the GC arm tended
to more frequent hospital admissions (P¼0.10).
Anticancer treatment beyond the trial regimens
Data on second-line chemotherapy and palliative radiotherapy
were available for 95% of the patients and showed no differences
between the treatment arms. In the VC vs GC arm, 46 vs 39%
(P¼0.08), 32 vs 25% (P¼0.23) and 15 vs 13% (P¼0.45) received
palliative radiotherapy, second-line chemotherapy, or both.
DISCUSSION
This randomised trial demonstrates that VC, when compared to
GC in NSCLC stage IIIB and IV, is equally effective (median and
2-year survival 7.3 months and 7% vs 6.5 months and 7%), but
causes significantly less grade 3–4 anaemia and thrombo-
cytopenia.
The main strength of the study is the highly representative
patient population. Roughly 40% of all stage IIIB and IV NSCLC
patients diagnosed in Norway during the study period were
included. Nearly one-third of the included patients had PS 2.
Further, the treatment arms were equivalent with respect to
chemotherapy delivery schedule, facilitating a direct comparison
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Figure 2 Overall survival according to treatment arms. (A) Survival for all study patients; VC (n¼218, censored n¼12) and GC (n¼214,
censored¼11). (B) Survival for PS 0/1 patients; VC (n¼156, censored n¼11) and GC (n¼153, censored n¼9).
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VC
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P=0.28 P=0.81  P=0.42  P=0.93 P=0.08
Nausea/vomiting
VC
GC
P=0.88  P=0.09 P=0.23 P=0.18 P=0.35
Dyspnoe LC13
VC
GC
P=0.48 P=0.26 P=0.31 P=0.29 P=0.90
Pain C30
VC
GC
P=0.81 P=0.24 P=0.81 P=0.74 P=0.64
Figure 3 Health-related quality of life scores (weeks 0–17) for global QOL, nausea/vomiting, pain, and dyspnoea according to treatment arm.
Table 2 Haematological toxicity according to treatment arm
VIN/CARBO GEM/CARBO
n¼216 n¼210
Grade 3 Grade 4 Grade 3 Grade 4
n % n % n % n % P
Anaemia 13 6 0 0 35 16 7 3 o0.01
Leucopoenia 82 38 16 7 57 27 6 3 o0.01
Thrombocytopenia 4 2 1 0.5 53 25 41 19 o0.01
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included at each of the smaller hospitals may be a weakness, but
constituted only 5% of the study population.
Vinorelbine combined with platinum has proved to be one of
the most promising regimens in the adjuvant setting (Douillard
et al, 2006), and vinorelbin-based therapy is established as a
valuable alternative in treatment of advanced NSCLC (Plessen et al,
2006). Gemcitabine is more frequently used in palliative treatment
of NSCLC. In a meta-analysis including 4556 patients from 13
randomised trials, gemcitabine-platinum doublets were found to
be slightly superior to the non-gemcitabine combinations regard-
ing progression-free survival only (Le Chevalier et al, 2005). When
compared to third-generation platinum-based doublets, the
difference was no longer significant (HR 0.93, CI 0.86–1.01).
Whether carboplatin may substitute cisplatin in two-drug
platinum-based combinations for advanced NSCLC was investi-
gated by Hotta et al (2004) in a meta-analysis including 2945
patients. It was concluded that cisplatin combined with a third-
generation agent produced a survival advantage of 11% when
compared to carboplatin and the same third-generation agent. The
recent CISCA (cisplatin vs carboplatin) meta-analysis (Ardizzoni
et al, 2006), an individual patient data meta-analysis presented at
ASCO 2006, found cisplatin-based chemotherapy superior to
carboplatin-based with respect to response rate, but not overall
survival. However, in palliative treatment of NSCLC, patient QOL,
treatment toxicity and time hospitalised are considered more
relevant issues.
The median survival in our study is somewhat lower when
compared to other phase III trials. For vinorelbine/platinum
combinations, recent phase III studies have yielded median
survival data ranging from 6.5 to 11 months (Wozniak et al,
1998; Kelly et al, 2001; Scagliotti et al, 2002; Fossella et al, 2003;
Gebbia et al, 2003; Georgoulias et al, 2005; Martoni et al, 2005; Tan
et al, 2005; Plessen et al, 2006). In the gemcitabine/platinum meta-
analysis (Le Chevalier et al, 2005), median survival in the
gemcitabine group was 9 months, reflecting the mean value for a
number of studies (Le Chevalier et al, 1994; Cardenal et al, 1999;
Sandler et al, 2000; Scagliotti et al, 2002; Schiller et al, 2002;
Alberola et al, 2003; Gebbia et al, 2003; Smit et al, 2003; Zatloukal
et al, 2003; Martoni et al, 2005; Rudd et al, 2005; Sederholm et al,
2005). Our shorter median survival is possibly explained by the
high proportion of patients with PS 2 (28%), which is the most
powerful predictor of survival in NSCLC patients (Stanley, 1980).
When PS 2 patients were excluded from our analysis, the median
survival was 9.0 vs 8.9 months in the VC and GC arm, respectively.
Nevertheless, this study shows that overall survival after VC is
equivalent to GC in an unselected lung cancer patient population
mimicking the everyday clinical setting.
The optimal duration of palliative therapy is debated. The 2003
update of the ASCO guidelines recommended limiting chemo-
therapy to six cycles in general and stopping treatment after four
cycles in stage IV patients who do not respond to treatment. This
limitation was based on a British trial comparing three vs six
courses of mitomycin, vinblastine and cisplatin (Smith et al, 2001),
and a US study comparing four courses of carboplatin/paclitaxel
with the same combination given until progression (Socinski et al,
2002). Neither trial showed benefits from longer treatment
duration. Additionally, the Norwegian Lung Cancer Study Group
recently published a study comparing three vs six courses of VC,
showing no benefit from the longer treatment (Plessen et al, 2006).
Consequently, we chose three course regimens for the current
study. The selected carboplatin and vinorelbine doses and schedule
in the present trial were based on this Norwegian study. The
gemcitabine dose resulted from a pilot study and the experience
from a phase II study (Kortsik et al, 2003). As 83% of the patients
in the VC arm and 78% in the GC arm tolerated all three courses,
doses and schedules appear appropriate for the study population.
The higher rate of leucopoenia experienced in the VC arm (45 vs
30%) did not result in higher infection rates and was mainly
laboratory toxicity without direct impact on patients’ lives. In
contrast, the markedly higher incidence of grade 3–4 anaemia (19
vs 6%) and thrombocytopenia (44 vs 3%) in the GC arm led to
additional symptoms and significantly more frequent transfusions
of blood products, requiring hospitalisation and further costs.
Haematological toxicity following VC treatment of 159 advanced
NSCLC patients was reported by Tan et al (2005). In this study,
the vinorelbine dose was higher (30mgm
 2), and inclusion
criteria were more restricted with Karnofsky PSX80 and age
o75. Leucopoenia was observed less often (22%) and grade 3–4
anaemia significantly more frequent (21%). The latter might
be explained by the somewhat higher vinorelbine dose. In
the previous Norwegian NSCLC study (Plessen et al, 2006),
the inclusion criteria were similar and 150 patients received
VC chemotherapy doses and schedule identical to the present
study. Plessen et al (2006) reported slightly less frequent grade 3–4
leucopoenia (35%), whereas the frequencies of grade 3–4 anaemia
and thrombocytopenia were similar. In a Swedish phase III
study in advanced NSCLC (Sederholm et al, 2005), GC treatment
yielded the same leucopoenia and thrombocytopenia rates as in
our study, but grade 3–4 anaemia was seen in only 5% of the
patients. The age distribution was comparable to our study, while
the proportion of PS 2 patients was smaller and fewer patients
had metastatic disease. Thus, our toxicity data are consistent
with previous studies and support the chosen chemotherapy
dosage.
The overall compliance rate regarding completion of the
HRQOL forms during the study period was 88%, which is equal
or better than previous lung cancer studies using the EORTC
questionnaire (Cardenal et al, 1999; Scagliotti et al, 2002; Gridelli
et al, 2003a,b; Smit et al, 2003; Rudd et al, 2005; Sederholm et al,
2005; Plessen et al, 2006). However, the higher frequency of
toxicity and interventions after GC therapy were not reflected in
any HRQOL difference between the treatment arms. Consistent
with the discussion by Scagliotti et al (2002), regarding their
comparison of gemcitabine-cisplatin and vinorelbine-cisplatin in
advanced NSCLC, the timing of HRQOL questionnaire completion
Table 3 Side effects and interventions secondary to haematological
toxicities according to treatment arm
Characteristics VC GC P
Thrombocytopenic bleeding
No. of patients bleeding 1 11 o0.01
Bleeding/patient 0.004 0.05
Missing (n)3 7
Neutropenic infections
No. of infections 46 48 0.98
Infections/patient 0.21 0.21
Missing (n)6 8
Hospital admissions
No. of admissions 80 102 0.10
Admission/patient 0.39 0.52
Missing (n)1 0 9
Blood transfusions
No. units 136 283 o0.01
Units/patient 0.65 1.36
Missing (n)2 3
Platelet transfusions
No. of units 5 30 0.02
Units/patient 0.03 0.15
Missing (n)1 6 1 6
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sat the end of each cycle may mask the effect of acute
chemotherapy-induced toxicity.
In conclusion, this randomised comparison of the two platinum-
based doublets with vinorelbine or gemcitabine showed equivalent
survival and HRQOL, while clinically relevant toxicity was more
frequent in the GC arm. To minimise toxicity-related burdens for
patients, the VC combination appears an appropriate choice for
palliative treatment of advanced NSCLC.
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